Jaw surgery showdown: three drugs battle for best visibility and least bleeding

NCT ID NCT06093893

Completed Symptom relief Sponsor: Boston Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study compared three common blood pressure-lowering drugs—dexmedetomidine, nicardipine, and labetalol—given during jaw surgery to see which one helps surgeons see better and reduces blood loss. 90 healthy adults having jaw surgery at Boston Medical Center were randomly assigned to one of the three drugs. The goal is to find the safest and most effective option for this type of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine, Nicardipine, Labetalol
What this could lead to: If successful, this could help surgeons choose the best drug for clearer visibility and less bleeding during jaw surgery.
What could go wrong: This is a small, completed Phase 4 trial with only 90 participants, so results may not apply to all patients or surgeries. Each drug also has its own side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTENSIVE ANESTHESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOTENSIVE ANESTHESIA ORTHOGNATHIC SURGERY

Contacts and locations

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.